Opportunity Overview
Moreover, I propose that the retention of 'poised' T cells and their in-situ localisation is influence by bidirectional signalling with the underlying stromal cells. In addition, as fibrosis progresses, I propose the function of TRM becomes dysregulated favouring the production of pro-fibrogenic mediators, that in turn enhance myofibroblast differentiation.
Collectively, by understanding the cellular crosstalk between ECM-producing stromal cells and TRM in the liver this research aims to reveal new anti-fibrotic approaches for clinical translation to promote fibrosis regression and limit ECM deposition - an urgent unmet clinical need.
This is one of 1,833 active United Kingdom Research Development opportunities most of your competitors will never see.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | Horizon Europe Guarantee |
|---|---|
| Country | United Kingdom |
| Category | Research Development |
| Published | April 30, 2023 |
| Procurement stage | Active solicitation |
| Response due | April 29, 2028 |
| Status | Open — accepting responses |
| Official source | View original notice |
| Last verified | August 10, 2026 |
Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.
Related Opportunities in United Kingdom
See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free United Kingdom Research Development intelligence report in your inbox
A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.